EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, CRVS: Corvus Pharma Com

30 Dec 25 10:52
LAST:

7.365

CHANGE:
 0.07		OPEN:
7.530		HIGH:
7.530		ASK:
10.150		VOLUME:
61.8K
CHG(%):
0.87		PREV:
7.430		LOW:
7.350		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
30 Dec 257.5307.5307.3507.36561.8K
29 Dec 257.7007.8557.3907.4501.45M
26 Dec 257.4807.7857.3207.7001.35M
24 Dec 257.3907.6257.3657.480448.6K
23 Dec 257.8007.8007.3407.370815.1K
22 Dec 257.6508.0007.4007.7851.16M
19 Dec 257.6207.9557.4607.4905.78M
18 Dec 257.8707.9997.4707.6401.91M
17 Dec 257.9108.0807.6307.8401.66M
16 Dec 258.4008.4757.8707.9403.23M

PROFILE

Name:Corvus Pharma Com
About:Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:901 Gateway Boulevard, South San Francisco, CA, United States, 94080
Website:https://www.corvuspharma.com
CUSIP:221015100
CIK:0001626971
ISIN:US2210151005
FIGI:BBG009F0TGH8
LEI:549300I3AVJ8F75NCX65

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-7.53 
Forward P/E:-16.75 
PEG Ratio:-0.18 
Price to Book:7.47 
Return on Assets:-0.29 
Return on Equity:-0.69 
EPS Ratio:-1.10 
EBITDA:5.91M 
Shares:74.51M 
Market Cap:548.8M 

TECHNICAL INDICATORS

MA5:7.481.5%
MA10:7.613.3%
MA20:8.059.4%
MA50:8.089.7%
MA100:7.093.8%
MA200:5.4634.9%
STO9:2.82 
STO14:1.46 
RSI14:25.10 
WPR14:-98.21 
MTM14:-1.10
ROC14:-0.13 
ATR:0.43 
Week High:7.866.7%
Week Low:7.320.6%
Month High:9.6030.3%
Month Low:7.3234.9%
Year High:9.6030.3%
Year Low:2.54190.0%
Volatility:18.39